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A B S T R A C T   
Background: Herpes zoster (HZ) risk is high in renal transplant recipients. Vaccination prior to transplantation 
may provide a useful strategy for the prevention of HZ in the posttranplantation period. However, it is not known 
whether immunity to varicella-zoster virus (VZV) is affected due to treatment surrounding transplantation. 
Methods: Both humoral and cellular immunity to VZV were determined prior to and 2–3 years after renal 
transplantation in 60 adult patients, and 62 matched healthy controls. VZV-specific cellular immunity was 
measured by an interferon gamma (IFNγ) enzyme-linked immunospot (ELISpot) assay and by analyzing T-cell 
functionality using flowcytometry. VZV-IgG levels were measured using an in-house glycoprotein enzyme-linked 
immunosorbent assay (gpELISA). 
Results: Using paired analysis, it was determined that numbers of IFNγ-producing cells did not change after 
transplantation, but were significantly lower in transplant recipients after transplantation than in controls (p =
0.028). Patients in whom the post-transplant period was complicated by rejection or any acute infection 
(excluding HZ) had a lower number of IFNγ-producing cells than patients who did not. VZV IgG levels did not 
differ from controls, but a significant decrease was observed after transplantation (p < 0.0001). 
Conclusions: VZV-specific cellular immunity, which is essential in the prevention of HZ, did not markedly change 
in patients following renal transplantation. This suggests that preventive vaccination before transplantation may 
be beneficial. Our results extend knowledge on VZV immunity after transplantation, vital when considering 
strategies for the prevention of HZ in these patients.   
1. Introduction 
Herpes zoster (HZ, shingles), characterized by neuralgia and a ve-
sicular rash, is due to reactivation of a latent varicella-zoster virus (VZV) 
infection. Neuralgia can last for months or even years, known as post-
herpetic neuralgia (PHN) (Gershon et al., 2010). The pain can have a 
major effect on a patients’ quality of life, and is often difficult to treat 
(Drolet et al., 2012). After VZV vaccination or a primary VZV infection 
the virus remains latently present for life in sensory neurons of the dorsal 
root ganglia (Gershon et al., 2010; Zerboni et al., 2014). Being inten-
sively treated with immunosuppressive medication, renal transplant 
recipients are known to be at increased risk of HZ. Incidence is estimated 
to be 28 to 37 per 1000 person years, which is 6–11 times higher than in 
the general population (Johnson et al., 2015). Also, a high prevalence of 
PHN of up to 48.7% has been reported (Pavlopoulou et al., 2015). 
Disseminated disease and visceral involvement are rare complications of 
HZ that occur mainly in immunocompromised patients and may have a 
lethal outcome (Yawn et al., 2007). 
Cellular immunity to VZV is considered to be essential in the immune 
response to VZV and prevention of HZ. Number and functionality of 
VZV-specific CD4+ T cells have been shown to be impaired in immu-
nocompromised patient groups at increased risk of HZ (Schub et al., 
2015). 
Currently, two types of zoster vaccine are licensed for the prevention 
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of HZ. The first is a live attenuated vaccine, containing the same virus 
strain as the childhood varicella vaccine, but 14 times more potent 
(Levin et al., 2008). It was shown to reduce incidence of HZ by 51% and 
of postherpetic neuralgia by 67% in healthy people above 60 years of 
age (Oxman et al., 2005). It also was shown to be effective in patients 
with end-stage renal disease (Tseng et al., 2016) and to increase 
VZV-specific humoral immunity in a small group of patients immunized 
prior to renal transplantation (Miller et al., 2018). However, the risk of 
live zoster vaccination in transplant recipients is demonstrated by a case 
report of an infection with the vaccine VZV strain shortly after vacci-
nation, in a 49-year old woman 4 years after receiving a renal transplant 
(Ortiz-Brizuela et al., 2019). 
More recently, a recombinant subunit zoster vaccine has been 
introduced, containing VZV envelope glycoprotein E and adjuvant sys-
tem AS01B. Studies in healthy persons above 50 years of age demon-
strate a higher efficacy than the live attenuated zoster vaccine (Lal et al., 
2015; Cunningham et al., 2016). Based on the limited available evidence 
on safety of zoster vaccination in patients on moderate to high doses of 
immunosuppressant therapy, the United States Advisory Committee on 
Immunization Practices (ACIP) in 2018 did not recommend either of the 
zoster vaccines (Dooling KL, Guo A, Patel M et al., 2018). Since then, 
Vink et al. published results of a study including 132 renal transplant 
recipients vaccinated using the recombinant subunit vaccine 4–18 
months after transplantation, and an equal number receiving placebo. 
Cellular immunity was analysed in 36 vaccinated and 32 controls, with 
satisfying results. There were no safety concerns, but patients with any 
autoimmune or potential immune-mediated disease were excluded 
(Vink et al., 2020). Although this novel vaccine seems promising, even 
following transplantation, the optimal timing of administration of zoster 
vaccination remains to be determined. 
To date, it is unclear how VZV-specific immunity evolves surround-
ing renal transplantation and consequently, whether zoster vaccination 
prior to transplantation could be efficacious to prevent HZ in transplant 
recipients. Aim of the current study therefore was to investigate VZV 
immunity before and after renal transplantation, in order to increase 
understanding of VZV-specific immune responses in this patient group. 
2. Methods 
2.1. Study population 
Eligible patients received a renal transplant in the University Medical 
Center Groningen (UMCG) between 2 and 3 years before inclusion and 
were still under supervision in this center. Blood was drawn at out- 
patient clinic visits. Peripheral blood mononuclear cells (PBMC) and 
serum samples of the same patients, collected before administering in-
duction therapy, immediately prior to the most recent transplantation, 
were retrieved from diagnostic archives. Healthy control subjects were 
age and sex-matched to patients. 
Immediately before and 4 days after renal transplantation standard 
induction therapy using basiliximab (anti-CD25; 2 doses of 20 mg) was 
administered. Immunosuppression after transplantation consisted of 
tacrolimus or cyclosporine, in combination with mycophenolate mofetil 
and prednisolone. Prednisolone dose was gradually tapered until a fixed 
dose of 5 mg. Anti-rejection therapy in 11 of 60 included patients 
generally consisted of intravenous prednisolone (1000 mg intravenously 
on three consecutive days, possibly repeated). Three of 11 patients 
received alemtuzumab (anti-CD52) and one received anti-thymocyte 
globulin next to prednisolone for treatment of acute rejection. 
The study was approved by the institutional review board of the 
University Medical Centre Groningen (METc 2014/305 and 2012/375). 
All patients and controls gave written informed consent. 
2.2. Clinical data, including occurrence of varicella, HZ and other 
infections 
Patient characteristics and medical history were retrieved from 
medical records. Furthermore, medical records were reviewed for 
occurrence of acute infections in the period between transplantation and 
study inclusion (2–3 years after transplantation). Seropositivity for 
herpes viruses, hepatitis viruses or BK virus were not regarded as acute 
infections. 
In addition to review of medical records, patients and controls were 
asked about their history of varicella and HZ using a questionnaire (in 
Dutch). In contrast to the United States, routine vaccination to prevent 
varicella in children is not practiced in The Netherlands (Wutzler et al., 
2017), and VZV immunity through natural infection is experienced in 
childhood (de Melker et al., 2006). 
2.3. Isolation, storage and thawing of PBMC and serum 
Immediately after collection of venous blood in lithium heparin 
containing tubes, PBMC were isolated according to standard protocols 
and stored in liquid nitrogen until use. Upon thawing, cell viability was 
evaluated by trypan blue staining, and was between 85 and 100%. 
Serum was stored at − 20 ◦C until use. 
2.4. Interferon-γ (IFNγ) ELISpot assay 
Interferon-γ (IFNγ) ELISpot assay was performed as previously 
described (Rondaan et al., 2014). In short, 2 × 105 PBMC (in 100 μl) 
were stimulated in duplicate using 10 μl UV-inactivated varicella vac-
cine (Provarivax; MSD, 1350 PFU/0.5 ml) in 200 μl endvolume or 5 
μg/ml of concanavalin A (positive control), while a negative control 
consisted of PBMC in culture medium alone. Spots were counted using 
an automated reader (AID EliSpot Reader; Autoimmun Diagnostika 
GmbH). Results were only accepted when concanavalin A yielded a 
positive result (see Supplemental Fig. S1). Mean number of spots in 
VZV-stimulated wells was corrected for mean number of spots in nega-
tive control wells. Results are referred to as number of IFNγ spot-forming 
cells per 2 × 105 PBMC. 
2.5. Flowcytometric analysis 
PBMC (1.2 × 106/tube) were stimulated using 20 μl UV-inactivated 
varicella vaccine, as positive control with 5 μg/ml staphylococcal 
enterotoxin B (SEB; Sigma-Aldrich) plus 1 μg/ml anti-CD28/CD49d 
(Beckton Dickinson (BD) or left unstimulated (negative control) in a 
total volume of 200 μl. PBMC were stimulated for 18 h, of which the last 
16 h in presence of 10 μg/ml brefeldin A (Sigma-Aldrich). Fluorescent T 
cell barcoding staining and immunostaining with anti-CD3 (clone SK7, 
BD), anti-CD8 (clone SK1, BD), anti-CD69 (clone FN50, BD), anti-IFNγ 
(clone B27, BD), anti-tumour necrosis factor alpha (TNFα) (clone 
Mab11, eBioscience) and anti-interleukin 2 (IL-2) (clone 599334, BD) 
was performed as described previously (Rondaan et al., 2018), with 
addition of anti-programmed cell death protein 1 (PD-1) and 
anti-cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) (clone 
C3D10, Biolegend). Data were collected for 1.0 × 106 events for each 
sample and plotted using Kaluza v1.2 (Beckman Coulter) (Supplemental 
Figs. 4 and 5 for gating examples). CD4+ T cell populations were gated as 
CD3+CD8− . Results were expressed as percentage of CD69+
cytokine/CTLA-4/PD-1 expressing CD4+ T cells within total CD4+ T cell 
population. 
2.6. Antibody levels to VZV 
VZV-specific IgG antibodies were quantified using an in-house 
glycoprotein (gp) enzyme-linked immunosorbent assay (ELISA), which 
was previously developed and validated using a quantitative Serion 
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classic VZV IgG ELISA (Institut Virion/Serion) and the institution’s 
standard diagnostic test for VZV serology (Rondaan et al., 2014). As 
antigen, VZV purified glycoproteins (EastCoastBio) were used. Pooled 
human serum with known levels of anti–glycoprotein VZV was used as 
standard. According to recommendations of Institut Virion/Serion, 
VZV-IgG levels above 100 mIU/ml were considered positive. 
2.7. Statistical analysis 
Wilcoxon signed rank test, intended for paired analyses, was used to 
compare continuous variables before and after transplantation. Results 
and characteristics of subgroups of patients were compared using a 
Mann-Whitney test or Fisher’s exact test. Comparisons between trans-
plant recipients (post-transplantation) and healthy control groups were 
done using Mann-Whitney U test or Fisher’s exact test when appropriate. 
For correlations, Spearman’s rho was used. P-values ≤0.05 (2-sided) 
were considered significant. Statistical analysis was performed using 
IBM SPSS Statistics 23 (IBM) and GraphPad Prism 7.02 (GraphPad 
Software, USA). 
3. Results 
3.1. Study population 
Characteristics of 60 renal transplant recipients and 62 healthy 
control subjects are summarized in Table 1. At time of inclusion, 2–3 
years after transplantation, only 1 (2%) transplant recipient was in need 
of renal replacement therapy, following rejection of the transplant kid-
ney. There were no significant differences in gender and age between 
patient and control group and between patients who experienced 
rejection or infection after transplantation and those who did not. 
3.2. Occurrence of HZ and other acute infections 
Questionnaire results, asking about history of varicella and HZ, were 
available for 53 (88%) of transplant recipients. Combined with results 
from medical record review, it was determined that 13 patients (22%) 
had a history of HZ. In four of these patients, timing was not known. In 
three HZ occurred before and in six within the 2–3 years after most 
recent transplantation. One patient experienced HZ only three weeks 
after transplantation, and another patient immediately after rejection 
therapy (with methylprednisolone and leflunomide). No HZ episodes 
occurred during prophylactic use of valganciclovir. 
Of the healthy control group, questionnaire results were available for 
32 (52%) persons. Four (13%) stated to have experienced HZ, of which 
one subject a few months prior to study participation, and the other 
three at least 15 years prior to study inclusion. 
Occurrence of acute infections in the 2–3 year period between 
transplantation and study inclusion is presented in Table 1. A more 
detailed summary is provided in Supplementary Table S2. 
3.3. Cellular immunity to VZV 
Number of IFNγ spot-forming cells in response to VZV stimulation 
did not significantly change following renal transplantation, but was 
lower in patients after transplantation than in healthy controls (p =
0.028) (Fig. 1A). Of note, before transplantation no significant differ-
ence compared to healthy controls was seen (p = 0.106). CMV status and 
history of more than one transplantation was found not to be of influ-
ence. The same held true for patients who were transplanted pre- 
emptively versus patients treated with renal replacement therapy prior 
to transplantation (data not shown). Interestingly, transplant recipients 
in whom post-transplantation period was complicated by a rejection 
episode were found to have a lower number of IFNγ spot-forming cells in 
response to VZV stimulation, which was significant prior to trans-
plantation. Patients with a HZ history were excluded from this analysis 
(Fig. 1B). 
Transplant recipients who experienced any acute infection other 
than HZ in 2–3 years post-transplantation (excluding those with a HZ 
history) also had lower numbers of IFNγ spot-forming cells in response 
to VZV stimulation than those who did not. This difference was not yet 
present in the same patients prior to transplantation (Fig. 1C). Analyzing 
data separately for viral or bacterial infections yielded similar results 
(data not shown). 
Occurrence of HZ within 2–3 years before blood drawing was not of 
influence on number of IFNγ spot-forming cells in response to VZV 
stimulation, but number of subjects was low (n = 6; Supplemental 
Fig. S3). 
Table 1 
Characteristics of healthy controls and transplant recipients.   
HC n = 62 Tx n = 60 
Female gender, no. (%) 33 (53) 30 (50) 








Cause of renal failure, no. (%) NA  
Glomerulonephritis  25 (42) 
IgA nephropathy 14 (23) 
MPGN 2 (3) 
FSGS 3 (5) 
Anti-GBM 1 (2) 
SLE 2 (3) 
AAV 2 (3) 
Cause unknown 1 (2) 
Genetic  7 (12) 
Vascular  4 (7) 
Diabetic nephropathy  5 (8) 
Congenital  2 (3) 
Urologic  3 (5) 
Chronic TIN  3 (5) 
Unknown  9 (15) 
Other  2 (3)a 
History of >1 transplant, no. (%) NA 15 (25)b 
RRT pre-Tx, no. NA  
None/HD/PD  17/29/14 
VZV serostatus 
Negative/positive 0/62 0/60 
CMV serostatus 
Negative/positive 31/15c 43/17 
Seroconversion in post-Tx period, no. (%) NA 11 (19) 
History of herpes zoster, no. (%) 4 of 32 (13) 13 (22)d 
Temporary (val)ganciclovir, no. (%)e NA 14 (23) 
No. (%) of patients with post-Tx 
complicationsf 
NA  
Rejection NA 11 (19) 
Infection, any/bacterial/viral/fungalg NA 40/25/27/4 
No.: number, Tx: transplantation, MPGN: membranoproliferative glomerulone-
phritis, FSGS: focal segmental glomerulosclerosis, GBM: glomerular basement 
membrane, SLE: systemic lupus erythematosus, AAV: ANCA-associated vascu-
litis, TIN: tubulointerstitial nephritis, RRT: renal replacement therapy, HD: 
haemodialysis, PD: peritoneal dialysis, VZV: varicella-zoster virus. 
a One patient developed renal failure because of acute tubulus necrosis (after 
acute aorta rupture surgery) and one patient underwent nephrectomy of his one 
functional kidney because of transitional cell carcinoma. 
b Two patients received a transplant organ other than kidney before their most 
recent renal transplantation; one received a heart transplant and one received 
multiple liver transplants. 
c Information on CMV status is missing for 16 persons in the HC-group. 
d In six patients, timing of herpes zoster was known to have occurred after 
most recent transplantation (within 2–3 years before study inclusion). 
e CMV-load was evaluated after transplantation. Patients with a positive load 
received (val)ganciclovir until CMV-load was <100 copies/ml twice. 
f Missing information on rejection in 2 patients and on infection (other than 
herpes zoster) in 1 patient. 
g More detailed information on the occurrence of infections in the 2–3 years 
after transplantation is provided in Supplementary Table S2. 
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3.4. Humoral immunity to VZV 
All patients and controls were VZV seropositive. After trans-
plantation VZV-IgG level was significantly lower than before trans-
plantation (p < 0.0001). There was no significant difference between 
healthy controls and transplant recipients (p = 0.149) (Fig. 2A). CMV 
status was found not to be of influence (data not shown). In contrast to 
cellular immunity results, humoral immunity to VZV was not found to be 
different in transplant recipients who experienced rejection of their 
transplant kidney (Fig. 2B). Although not statistically significant, pa-
tients that experienced an acute infection other than HZ tended to have 
higher antibody levels to VZV than patients without any documentation 
of acute infections in their records (Fig. 2C). 
3.5. Increased percentages of cytokine-expressing T cells prior to renal 
transplantation 
Upon stimulation with VZV, significantly higher percentages of 
CD4+ T cells producing TNFα and IL-2 were found in patients prior to 
transplantation. This was also seen for IL-2 upon polyclonal stimulation 
using SEB (Fig. 3A and B). TNFα expression was significantly higher 
compared to HC after SEB stimulation. 
Similar percentages of IFNγ-producing CD4+ T cells after VZV and 
SEB stimulation were found before and after transplantation. Also, no 
difference in percentage of T cells producing this cytokine were found 
between transplant recipients and control subjects (Fig. 3A and B). 
3.6. Expression of PD-1 and CTLA-4 before and after transplantation 
Mean fluorescence intensity (MFI) of programmed cell death protein 
1 (PD-1) was higher in VZV-specific cells than in polyclonal stimulated 
cells. No differences between transplant recipients and control subjects 
were observed for PD-1 expression (Fig. 4A). Cytotoxic T-lymphocyte- 
associated protein 4 (CTLA-4) MFI on CD4+ T cells was significantly 
increased in patients after transplantation, both after VZV and SEB 
stimulation (Fig. 4C). Percentages of T cells expressing PD-1 were also 
higher after VZV stimulation compared to SEB stimulation, and 
increased compared to HC after SEB stimulation (Fig. 4B). Percentages 
of CTLA-4 positive cells increased after transplantation, but remained 
lower compared to HC (Fig. 4D). 
3.7. Correlations 
An inverse correlation between age and cellular immunity to VZV 
(number of IFNγ spot-forming cells) (ρ = − 0.389, p = 0.002) was pre-
sent in transplant recipients (post-Tx), which was not seen in controls or 
Fig. 1. Numbers of interferon-γ (IFNγ) spot-forming cells in response to VZV stimulation in (A) 55/62 healthy control (HC) subjects and 58/59 patients before 
(pre) and 2–3 years after transplantation (Tx), (B) 8 patients that experienced a rejection episode and 35–37 patients who did not, before (pre) and 2–3 years after 
transplantation (Tx), (C) 25/27 patients that experienced an acute infection (excluding herpes zoster) in the post-transplantation period and 19 patients who did not, 
before (pre) and 2–3 years after transplantation (Tx). Patients with a history of herpes zoster were excluded from analysis. Lines show the median. 
Fig. 2. Levels of anti-glycoprotein (gp)VZV IgG presented on a log-scale in (A) 55/62 healthy control (HC) subjects and 58/59 patients before (pre) and 2–3 years 
after transplantation (Tx), (B) 8 patients that experienced a rejection episode and 35/37 patients who did not, before (pre) and 2–3 years after transplantation (Tx), 
(C) 27 patients that experienced an acute infection (excluding herpes zoster) in the post-transplantation period and 19 patients who did not, before (pre) and 2–3 
years after transplantation (Tx). Patients with a history of herpes zoster were excluded from analysis. 
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prior to transplantation. No significant correlations were found between 
age and humoral immunity to VZV, or between humoral and cellular 
immunity to VZV (data not shown). 
4. Discussion 
In this study VZV-specific immunity was evaluated in 60 patients 
before and after renal transplantation. Cellular immunity to VZV, as 
assessed by IFNγ ELISpot assay, did not significantly change after 
transplantation, but was significantly lower in patients after trans-
plantation than in control subjects. VZV-specific humoral immunity in 
transplant recipients did not differ from controls, but a significant 
decrease was observed after transplantation. 
Cellular immunity to VZV, and especially CD4+ T cells, is considered 
Fig. 3. Frequencies of cytokine-producing CD4þ T cells per total CD4+ T cells upon stimulation with varicella-zoster virus (VZV) (3A), and upon stimulation with 
staphylococcal enterotoxin B (SEB, positive control) (3B) in 56 healthy control subjects (HC) and 59 patients before (pre) and 2–3 years after (post) receiving a renal 
transplant. Bars show the median and interquartile range. IFNγ = interferon gamma; TNFα = tumor necrosis factor alpha; IL-2 = interleukin-2. 
Fig. 4. Mean fluorescence intensity (MFI: A,C) and percentages of CD4þ T cells positive expressing (%, B, D) programmed cell death protein 1 (PD-1) and 
cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) upon stimulation with varicella-zoster virus (VZV) and staphylococcal enterotoxin B (SEB, positive control) 
in 28 healthy control subjects (HC) and 59 patients before (pre) and 2–3 years after (post) receiving a renal transplant. Bars show the median and interquartile range. 
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to be essential in immune response to VZV and prevention of HZ (Schub 
et al., 2015). Responding cells in IFNγ ELISpot assay consist mostly of 
CD4+ T cells. This assay, which tests functionality of antigen-specific 
cells, is generally considered to be a reliable method for assessment of 
virus-specific cellular immunity (Karlsson et al., 2003). Previously, 
decreased numbers of IFNγ spot-forming cells upon VZV stimulation 
have been demonstrated in elderly persons and different immunocom-
promised patient groups at increased risk of HZ (Rondaan et al., 2014; 
Shirane et al., 2017). Our finding of a lower number of IFNγ 
spot-forming cells upon VZV stimulation in transplant recipients 
compared to controls is in line with the reported increased HZ incidence 
in this group (Arness et al., 2008; Pavlopoulou et al., 2015). Interest-
ingly, in response to VZV stimulation a lower number of IFNγ 
spot-forming cells was present in transplant recipients in whom 
post-transplant period was complicated by rejection or acute infections 
other than HZ. Anti-rejection therapy was previously identified to be a 
significant risk factor for development of HZ in renal transplant re-
cipients (Pavlopoulou et al., 2015), but as the difference was also pre-
sent before transplantation this could indicate that a suboptimal 
immune system is already present in these patients prior to trans-
plantation. The lower number of IFNγ spot-forming cells in response to 
VZV stimulation in patients who experienced acute infection in the years 
following transplantation may be a reflection of a defective 
cell-mediated immunity in general, and therefore a higher susceptibility 
to infection. The finding was accompanied by a slightly higher 
(non-significant) VZV-IgG level in patients who experienced infection. 
We speculate this might be caused by subclinical reactivations of VZV in 
immunocompromised hosts, as already described by Ljungman et al., in 
1986 (Ljungman et al., 1986). 
Age is a well-known risk factor for HZ, and has been shown to be 
associated with impaired cellular immunity to VZV (Tang et al., 2012). 
This is in line with our finding of an inverse correlation between number 
of IFNγ spot-forming cells and age of transplant recipients. 
Next to evaluating cellular immunity to VZV using an IFNγ ELISpot 
assay, we evaluated cytokine production of CD4+ T cells in response to 
stimulation with VZV. Cytokine production was shown to be high prior 
to transplantation, but did not differ between transplant recipients and 
control subjects. As this phenomenon was also seen upon polyclonal 
stimulation, it was not VZV-specific. Hypercytokinaemia could be an 
explanation of our findings, which is known to occur in chronic kidney 
disease patients, and is associated with uraemia, which causes activation 
and decreased functions of all immune cells (Betjes, 2013). 
Upregulation of inhibitory receptors such as PD-1 and CTLA-4 has 
been identified as an important feature of exhausted T cells. Exhausted T 
cells, resulting from a persistent (viral) infection, are less able to exert 
their effector functions (Kahan et al., 2015). As we found expression of 
inhibitory receptor PD-1 to be similar in transplant recipients and con-
trols, we could not confirm the finding of an increased PD-1 expression 
on CD4+ T cells in transplant recipients upon polyclonal stimulation, as 
reported by Schub et al. Notablyu PD-1 expression during active HZ 
however. (Schub et al., 2015). Mean fluorescence intensity of PD-1 was 
higher upon VZV stimulation than upon polyclonal stimulation. This 
may be explained by the physiologic role of PD-1 in the regulation of 
immune responses towards a specific antigen (Teigler et al., 2017). 
Expression and percentage of CTLA-4 however was increased after 
transplantation both after VZV and polyclonal stimulation. Checkpoint 
inhibitors are currently considered as immunomodulators in the case of 
tolerance induction in transplantation (Mardomi et al., 2020). 
Our results are in line with those of a study by Kho et al. (2017), in 
which adult renal transplant candidates with undetectable VZV-IgG 
levels, were vaccinated using a live attenuated varicella vaccine. 
Cellular immunity to VZV was evaluated in 11 patients before vacci-
nation and after transplantation (median 7.2 months after trans-
plantation). While the total number of leukocytes decreased, the 
percentage of VZV-specific CD4+ memory T cells was shown to signifi-
cantly increase, suggesting that VZV-specific cellular immunity is able to 
persist during renal transplantation. 
This study has limitations. Firstly, information regarding HZ and 
other infections could have been missing from medical records as these 
do not necessarily come to attention of a hospital specialist. Question-
naire results on HZ occurrence may not be completely reliable. 
Furthermore, differences in VZV-immunity between diagnostic sub-
groups could not be reliably evaluated because of the limited number of 
patients in the different subgroups. Medium alone is not the optimal 
negative control as UV-inactivated varicella vaccine that was used for 
stimulations contains substances other than VZV that might lead to VZV- 
independent T cell stimulation. Using varicella vaccine as an in vitro 
stimulus may lead to different results than when using the more physi-
ologic, wild type varicella virus. Lastly, T cell tests are not standardized 
and results differ greatly between publications. 
In conclusion, this study has added to the knowledge on the influence 
of transplantation on VZV immunity, which is important to understand 
the high HZ risk in renal transplant recipients and when considering 
strategies for prevention of HZ in these patients. 
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